The global liver fibrosis treatment market size is accounted at USD 20.35 billion in 2025 and is forecasted to hit around USD 52.26 billion by 2034, representing a notable CAGR of 11.05% from 2025 to 2034. The North America market size was estimated at USD 6.96 billion in 2024 and is expanding at a CAGR of 11.19% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Liver Fibrosis Treatment Industry Impact
5.2. COVID-19 - Impact Assessment for the Industry
5.3. COVID-19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Liver Fibrosis Treatment Market, by Treatment Type, 2025-2034
8.1.1 Peroxisome Proliferator-Activated Receptors (Par)-Alpha Agonist
8.1.1.1. Market Revenue and Forecast (2022-2034)
8.1.2. Ace Inhibitors
8.1.2.1. Market Revenue and Forecast (2022-2034)
8.1.3. Hepatotropic Drug
8.1.3.1. Market Revenue and Forecast (2022-2034)
8.1.4. Others
8.1.4.1. Market Revenue and Forecast (2022-2034)
9.1. Liver Fibrosis Treatment Market, by Condition, 2025-2034
9.1.1. Chronic Liver Diseases
9.1.1.1. Market Revenue and Forecast (2022-2034)
9.1.2. Hepatitis C
9.1.2.1. Market Revenue and Forecast (2022-2034)
9.1.3. Nonalcoholic Steatohepatitis
9.1.3.1. Market Revenue and Forecast (2022-2034)
10.1. Liver Fibrosis Treatment Market, by End User, 2025-2034
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast (2022-2034)
10.1.2. Specialty Clinics
10.1.2.1. Market Revenue and Forecast (2022-2034)
10.1.3. Others
10.1.3.1. Market Revenue and Forecast (2022-2034)
11.1. North America
11.1.1. Market Revenue and Forecast, by Treatment Type (2022-2034)
11.1.2. Market Revenue and Forecast, by Condition (2022-2034)
11.1.3. Market Revenue and Forecast, by End User (2022-2034)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Treatment Type (2022-2034)
11.1.4.2. Market Revenue and Forecast, by Condition (2022-2034)
11.1.4.3. Market Revenue and Forecast, by End User (2022-2034)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Treatment Type (2022-2034)
11.1.5.2. Market Revenue and Forecast, by Condition (2022-2034)
11.1.5.3. Market Revenue and Forecast, by End User (2022-2034)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Treatment Type (2022-2034)
11.2.2. Market Revenue and Forecast, by Condition (2022-2034)
11.2.3. Market Revenue and Forecast, by End User (2022-2034)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Treatment Type (2022-2034)
11.2.4.2. Market Revenue and Forecast, by Condition (2022-2034)
11.2.4.3. Market Revenue and Forecast, by End User (2022-2034)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Treatment Type (2022-2034)
11.2.5.2. Market Revenue and Forecast, by Condition (2022-2034)
11.2.5.3. Market Revenue and Forecast, by End User (2022-2034)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Treatment Type (2022-2034)
11.2.6.2. Market Revenue and Forecast, by Condition (2022-2034)
11.2.6.3. Market Revenue and Forecast, by End User (2022-2034)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Treatment Type (2022-2034)
11.2.7.2. Market Revenue and Forecast, by Condition (2022-2034)
11.2.7.3. Market Revenue and Forecast, by End User (2022-2034)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Treatment Type (2022-2034)
11.3.2. Market Revenue and Forecast, by Condition (2022-2034)
11.3.3. Market Revenue and Forecast, by End User (2022-2034)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Treatment Type (2022-2034)
11.3.4.2. Market Revenue and Forecast, by Condition (2022-2034)
11.3.4.3. Market Revenue and Forecast, by End User (2022-2034)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Treatment Type (2022-2034)
11.3.5.2. Market Revenue and Forecast, by Condition (2022-2034)
11.3.5.3. Market Revenue and Forecast, by End User (2022-2034)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Treatment Type (2022-2034)
11.3.6.2. Market Revenue and Forecast, by Condition (2022-2034)
11.3.6.3. Market Revenue and Forecast, by End User (2022-2034)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Treatment Type (2022-2034)
11.3.7.2. Market Revenue and Forecast, by Condition (2022-2034)
11.3.7.3. Market Revenue and Forecast, by End User (2022-2034)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Treatment Type (2022-2034)
11.4.2. Market Revenue and Forecast, by Condition (2022-2034)
11.4.3. Market Revenue and Forecast, by End User (2022-2034)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Treatment Type (2022-2034)
11.4.4.2. Market Revenue and Forecast, by Condition (2022-2034)
11.4.4.3. Market Revenue and Forecast, by End User (2022-2034)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Treatment Type (2022-2034)
11.4.5.2. Market Revenue and Forecast, by Condition (2022-2034)
11.4.5.3. Market Revenue and Forecast, by End User (2022-2034)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Treatment Type (2022-2034)
11.4.6.2. Market Revenue and Forecast, by Condition (2022-2034)
11.4.6.3. Market Revenue and Forecast, by End User (2022-2034)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Treatment Type (2022-2034)
11.4.7.2. Market Revenue and Forecast, by Condition (2022-2034)
11.4.7.3. Market Revenue and Forecast, by End User (2022-2034)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Treatment Type (2022-2034)
11.5.2. Market Revenue and Forecast, by Condition (2022-2034)
11.5.3. Market Revenue and Forecast, by End User (2022-2034)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Treatment Type (2022-2034)
11.5.4.2. Market Revenue and Forecast, by Condition (2022-2034)
11.5.4.3. Market Revenue and Forecast, by End User (2022-2034)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Treatment Type (2022-2034)
11.5.5.2. Market Revenue and Forecast, by Condition (2022-2034)
11.5.5.3. Market Revenue and Forecast, by End User (2022-2034)
12.1. Gilead Sciences, Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Merck & Co., Inc.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Bristol-Myers Squibb
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Johnson and Johnson
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Novartis AG
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Vertex Pharmaceuticals Incorporated
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Pfizer Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. FibroGen, Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Inventiva Pharma
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Pharmaxis Limited
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample